Login
Companies $IBIO
$0.71 -$0.00 (0.1%) After hours
iBio, Inc. logo

iBio, Inc.

ibioinc.com

What Do They Do?

Develops antibody drug candidates using artificial intelligence to treat obesity and related metabolic and heart-lung diseases.

How Do They Make Money?

It charges a fixed amount for a project deliverable, typically after completion and delivery; research collaborations may also bring milestone payments tied to future development events.

FY2026 revenue

Who Are Their Customers?

Works with research collaborators on antibody programs; it also seeks partners for selected drug candidates and for use of its discovery and screening technologies.

Do Revenues Turn Into Profits?

No. It lost $33M in FY2026.

Operating income, FY2026
−35141% of revenue
▼ −89% (Loss) vs FY2025 (−$18.6M, −4651%)
Net income, FY2026
−33044% of revenue
▼ −80% (Loss) vs FY2025 (−$18.4M, −4594%)
Free cash flow, FY2026
−23796% of revenue
▼ −55% (Loss) vs FY2025 (−$15.3M, −3830%)

How Are They Changing?

Since the FY2026 annual report
Latest quarter: Q1 FY2027, the three months to Sep 30, 2026
Revenue
▲ +975%
vs $100K in Q1 FY2026
Net income
▼ −32% (Loss)
vs −$5.7M in Q1 FY2026

Shrinking. Revenue fell 95% in 4 years, from $1.9M in FY2022 to $100K in FY2026, about 52% a year.

Therapeutic focus The earlier report focused its in-house programs on oncology; the latest report centers on antibody medicines for obesity and related metabolic and heart-lung diseases.

Who Do They Compete With?

Competes with Eli Lilly, Novo Nordisk, Amgen, Bristol-Myers Squibb, Merck &, Novartis, MedImmune, Johnson & Johnson, Pfizer, Merck, Sanofi, Genentech, Regeneron, Keros Therapeutics, Scholar Rock, Biohaven, Basecure Therapeutics, Structure Therapeutics, Viking Therapeutics, and Veru

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support